medigraphic.com
ISSN 0016-3813 (Print)

2018, Number 6

<< Back Next >>

Gac Med Mex 2018; 154 (6)

Breve recorrido histórico de la enfermedad de Parkinson a 200 años de su descripción

Arredondo-Blanco K, Zerón-Martínez R, Rodríguez-Violante M, Cervantes-Arriaga A

Language: Spanish
References: 75
Page: 719-726
PDF size: 201.24 Kb.


ABSTRACT

The original description of what currently is known as Parkinson’s disease was published 200 years ago. During both these centuries, knowledge on symptomatology, pathophysiology, genetics and pharmaceutical and surgical treatment has significantly increased; however, this nosological entity continues to be of imprecise origin and progressive evolution. In the present review, the historical events that contributed to describe and improve the understanding of this disease are summarized.


REFERENCES

  1. Keppel-Hesselink JM. Evolution of concepts and definitions of Parkinson’s disease since 1817. J Hist Neurosci. 1996; 5:200-207.

  2. Hurwitz B. Urban observation and sentiment in James Parkinson’s essay on the shaking palsy (1817). Lit Med. 2014;32:74-104.

  3. Parkinson J. Definition, history, illustrative cases. En: An essay on shaking palsy. Londres: Whittingham and Rowland; 1817.

  4. León R. Historia de la levodopa; un tratamiento anunciado desde la antigüedad. AFT. 2007;5:205-207.

  5. García P. Prehistoria de la enfermedad de Parkinson. Neurologia. 2004;19:735-737.

  6. Jonker MA. Estimation of life expectancy in the Middle Ages. J R Statist Soc A. 2003;166:105-117.

  7. Rosler R, Young P. La lección de anatomía del doctor Nicolaes Tulp: el comienzo de una utopía médica. Rev Med Chile. 2011;139:535-541.

  8. Charcot JM. Lecture VII: On slow compression of the spinal cord. En: Lectures on the diseases of the nervous system. Londres: New Sydenham Society; 1881.

  9. Charcot JM. De la paralysie agitante. En: Oeuvres complètes. Leçons sur les maladies du système nerveux. Tomo I. París: Bureaux du Progrès Médical; 1892. pp. 155-188.

  10. Lewy FH. Zur pathologischen Anatomie der Paralysis agitans. Deutsche Zeitschrift für Nervenheilkunde. 1913;50:50-55.

  11. Trétiakoff K. Contribution à l’étude de l’anatomie pathologique du locus niger de Soemmering avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. Francia: Universidad de París; 1919.

  12. Bethlem J, Den-Hartog-Jager WA. The incidence and characteristics of Lewy bodies in idiopathic paralysis agitans (Parkinson’s disease). J Neurol Neurosurg Psychiatry. 1960;23:74-80.

  13. Braak H, Del-Tredici K, Rüb U, De-Vos RA, Jansen-Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197-211.

  14. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-980.

  15. Angot E, Steiner JA, Hansen C, Li JY, Brundin P. Are synucleinopathies prion-like disorders? Lancet Neurol. 2010;9:1128-1138.

  16. Hasegawa M, Nonaka T, Masuda-Suzukake M. Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders. Pharmacol Ther. 2017;172:22-33.

  17. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dutra A, Pike B, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045-2047.

  18. Nussbaum RL, Polymeropoulos MH. Genetics of Parkinson’s disease. Hum Mol Genet. 1997;6:1687-1691.

  19. Jones AC, Yamamura Y, Almasy L, Bohlega S, Elibol B, Hubble J, et al. Autosomal recessive juvenile parkinsonism maps to 6q25.2-q27 in four ethnic groups: detailed genetic mapping of the linked region. Am J Hum Genet. 1998;63:80-87.

  20. Bonifati V, Rizzu P, Van-Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256-259.

  21. Hatano Y, Li Y, Sato K, Asakawa S, Yamamura Y, Tomiyama H, et al. Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol. 2004;56:424-427.

  22. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601-607.

  23. Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry. 2004; 75:1672-1677.

  24. Guebila MB, Thiele I. Model-based dietary optimization for late-stage, levodopa-treated, Parkinson’s disease patients. NPJ Syst Biol Appl. 2016;2:16013.

  25. Nagashima Y, Kondo T, Sakata M, Koh J, Ito H. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson’s disease: in relation to the effects of Mucuna pruriens. J Neurol Sci. 2016;361:229-234.

  26. Ordenstein L. Étiologie, pronostic, thérapeutique. En: Sur la paralysie agitante et la sclérose plaque généralisée. Francia: A Delahaye, Libraire- Éditeur; 1868.

  27. Charcot JM. Leçon 5. En: Oeuvres complètes de J.M. Leçons sur les maladies du système nerveux. Tomo I. Bureaux du Progrès Médical; París: 1892.

  28. Gowers WR. Paralysis agitans. En: A system of medicine. Londres: Macmillan; 1899.

  29. Gowers WR. Paralysis agitans. En: A manual of diseases of the nervous system. Londres: J. & A.; 1888.

  30. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson’s disease. Mov Disord. 2008;23:497-508.

  31. Carlsson A, Waldeck B. A fluorimetric method for the determination of dopamine (3‐hydroxytyramine). Acta Physiol Scand. 1958;44:293-298.

  32. Price KS, Farley IJ, Hornykiewicz O. Neurochemistry of Parkinson’s disease: relation between striatal and limbic dopamine. Adv Biochem Psychopharmacol. 1978;19:293-300.

  33. Lloyd K, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson’s disease: effect of L-dopa therapy. J Pharmacol Exp Ther. 1975;195:453-464.

  34. Ehringer H, Hornykiewicz, O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Parkinsonism Relat Disord. 1960;4:53-57.

  35. Montagu KA. Catechol compounds in rat tissues and in brains of different animals. Nature. 1957;180:244-245.

  36. Blaschko H. The specific action of L-dopa decarboxylase. J Physiol. 1939;96:50-51.

  37. Holtz P. Dopa decarboxylase. Naturwissenschaften. 1939;27:724-725.

  38. Cotzias GC, Van-Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276:374-379.

  39. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism: chronic treatment with L-dopa. N Engl J Med. 1969;280:337-345.

  40. Fahn S. Parkinson disease the effect of levodopa and the ELLDOPA trial. Earlier vs later L-dopa. Arch Neurol. 1999;56 529-535.

  41. Doshay LJ, Constable K. Newer drugs in the treatment of parkinsonism. Neurology. 2001;57:4-10.

  42. Corbin KB. Trihexyphenidyl; evaluation of the new agent in the treatment of Parkinsonism. J Am Med Assoc. 1949;141:377-382.

  43. Bertol E, Fineschi V, Karch SB, Mari F, Riezzo I. Nymphaea cults in ancient Egypt and the New World: a lesson in empirical pharmacology. J R Soc Med. 2004;97:84-85.

  44. Taba P, Lees A, Stern G. Erich Harnack (1852-1915) and short history of apomorphine. Eur Neurol. 2013;69:321-324.

  45. Matthiessen A. Researches into the chemical constitution of the opium bases. Part I.- On the action of hydrochloric acid on morphia. Proc R Soc Lond. 1868;17:455-460.

  46. Matthiessen A, Wright C. Apomorphia, a new base derived from morphine. Pharm J Tr. 1869;11-12.

  47. Djamshidian A, Poewe W. Apomorphine and levodopa in Parkinson’s disease: two revolutionary drugs from the 1950’s. Parkinsonism Relat Disord. 2016;33:S9-S12.

  48. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc. 1951;56:251-253.

  49. Ernst AM. Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS. Psychopharmacologia. 1965;7:391-399.

  50. Cotzias GC, Düby S, Ginos JZ, Steck A, Papavasiliou PS. Dopamine analogues for studies of parkinsonism. N Engl J Med. 1970;283:1289.

  51. Cotzias GC, Papavasiliou PS, Tolosa ES, Mendez JS, Bell-Midura M. Treatment of Parkinson’s disease with aporphines: Possible role of growth hormone. N Engl J Med. 1976;294 567-572.

  52. Stibe C, Lees A, Stern G. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet. 1987;1:871.

  53. Lees AJ, Haddad S, Shaw KM, Kohout LJ, Stern GM. Bromocriptine in parkinsonism: a long-term study. Arch Neurol. 1978;35 503-505.

  54. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induced less dyskinesia than L‐dopa in the MPTP‐treated marmoset. Mov Disord. 1998;13:234-241.

  55. Rascol O, Pathak A, Bagheri H, Montastruc JL. Dopaminagonists and fibrotic valvular heart disease: further considerations. Mov Disord. 2004;19:1524-1425.

  56. Hobson DE, Pourcher E, Martin WR. Ropinirole and pramipexole, the new agonists. Can J Neurol Sci. 1999;26:S27-S33.

  57. Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, et al. Continuous transdermal dopaminergic stimulation in advanced Parkinson’s disease. Clin Neuropharmacol. 2001;24:163-169.

  58. Pfeiffer RF. Potential of transdermal drug delivery in Parkinson’s disease. Drugs Aging. 2002;19:561-570.

  59. Jenner P, Könen-Bergmann, M, Schepers C, Haertter S. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther. 2009;31:2698-2711.

  60. Auffret M, Le-Jeune F, Maurus A, Drapier S, Houvenaghel JF, Robert GH, et al. Apomorphine pump in advanced Parkinson’s disease: Effects on motor and nonmotor symptoms with brain metabolism correlations. J Neurol Sci. 2017;372:279-287.

  61. Bar Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 2004;355:169-172.

  62. Schwab RS, England AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969;208:1168-1170.

  63. Foerster O, Penfield W. The structural basis of traumatic epilepsy and results of radical operation. Brain 1930; 53:99-119.

  64. Meyers RA. Surgical procedure for the alleviation of postencephalitic tremor, with notes on the physiology of premotor fibers. Arch Neurol Psychiatry. 1940;44:455-459.

  65. Bucy PC, Case TJ. Tremor, physiologic mechanism and abolition by surgical means. Archi Neurol. 1939;41:721-746.

  66. Klemme RM. Surgical treatment of dystonia, paralysis agitans and athetosis. Arch Neurol Psychiatry. 1940;44:926.

  67. Spiegel EA, Wycis HT, Marks M, Lee AJ. Stereotaxic apparatus for operations on the human brain. Science. 1947;106:349-350.

  68. Cooper IS. Ligation of the anterior choroidal artery for involuntary movements; parkinsonism. Psychiatr Q. 1953;27:317-319.

  69. Hassler R. The influence of stimulations and coagulations in the human thalamus on the tremor at rest and its physiologic mechanism. Proc Second Intl Congr Neuropath. 1:637-642.

  70. Laitinen LV, Bergenheim AT, Hariz MI. Leksell’s posteroventral pallidotomy in the treatment of Parkinson’s disease. J Neurosurg. 1992;76:53-61.

  71. Smith Y, Parent A. Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Res. 1988;453:353-356.

  72. Rodríguez-Oroz MC, Rodríguez M, Guridi J, Mewes K, Chockkman V, Vitek J, et al. The subthalamic nucleus in Parkinson’s disease: somatotopic organization and physiological characteristics. Brain. 2001; 124:1777-1790.

  73. Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord. 1991;6:288-289.

  74. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 1990;249: 1436-1438.

  75. Pollak P, Benabid AL, Gross C, Gao DM, Laurent A, Benazzouz A, et al. Effects of the stimulation of the subthalamic nucleus in Parkinson disease. Rev Neurol (Paris). 1993;149:175-176.




2020     |     www.medigraphic.com